CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 136 enrolled
Drug / intervention
VGodevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03495908
NCT03495908N/ACompleted
CompareCT.gov

Efficacy and Safety Comparison Between U-100 Regular Human Insulin and Rapid Acting Insulin When Delivered by VGo Wearable Insulin Delivery in Type 2 Diabetes

East Coast Institute for Research·interventional·Posted Apr 12, 2018·Updated Mar 2, 2021

In Brief

A clinical study evaluating VGo for Type 2 Diabetes and Type 2 Diabetes Mellitus. Completed, enrolled 136 participants across 2 sites.

Detailed Summary

The purpose of the study is to collect data about how well U-100 Regular Human Insulin can be used in the V-Go Insulin Delivery Device compared to U-100 Rapid Acting Insulin in the V-Go Insulin Delivery Device. The data collected will be used to see how much subjects' blood sugar levels change over time after they switch from using U-100 Rapid Acting Insulin to U-100 Regular Human Insulin within their V-Go Insulin Delivery Device.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes, Type 2 Diabetes Mellitus
CountriesUnited States
CollaboratorsValeritas, Inc., Dallas Diabetes Research

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedApr 12, 2018
Enrollment StartApr 9, 2018
Primary CompletionAug 12, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.2 years ago

Interventions

VGodevice

Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.